Dennis A. Gastineau, M.D., established the Human Cellular Therapy Laboratory in the Division of Transfusion Medicine at Mayo Clinic's campus in Rochester, Minnesota, for the purpose of translating cell-based novel therapies into products appropriate for administration to patients.
Dr. Gastineau has established a sister laboratory at Mayo Clinic's campus in Phoenix/Scottsdale, Arizona, to enable multisite trials of novel therapies and bring new treatments to the Southwest.
- Immunotherapy and cancer vaccines
- Immunomodulation, involving treatment of inflammatory bowel disease complications, graft-versus-host disease and induction of immune tolerance
- Translational assistance to investigators, assuring that processes comply with the Current Good Manufacturing Practices (CGMP) of the Food and Drug Administration (FDA)
Significance to patient care
The Human Cellular Therapy Laboratory was the first contract manufacturer for Dendreon Corp., bringing the first FDA-approved cellular immunotherapy for prostate cancer to market.
The laboratory has held or participated in more than 20 investigational new drug trials designed to treat neurodegenerative diseases, renal disease, inflammatory bowel disease, graft-versus-host disease, lymphoma, glioblastoma and ovarian cancer.
The laboratory endeavors to partner in bringing first-in-human treatments to Mayo Clinic's patients.
- President, Foundation for the Accreditation of Cellular Therapy, the accrediting body for cellular therapy and bone marrow transplant programs, 2016-2018